Back to News
Market Impact: 0.1
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Source: globenewswire.com
Healthcare & Biotech
Optimi Health Corp., a commercial-stage manufacturer of regulated psychedelic pharmaceutical products, announced it will participate in an H.C. investor event. The announcement provides limited new financial or operational information and is unlikely to materially affect valuation or near-term trading.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
OPTH0.10
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI